Browse by ▼

Vertex Pharmaceuticals

  • Did This Stock Deserve This Sudden Upward Swing?

    By Jeremiah Feliciano - May 8, 2013 | Tickers: MNKD, NVS, VRTX

    Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged from $52.87 on April 18 to a 12-year high of $85.90 per share on April 19 after the company reported positive outcomes from the Phase II clinical trial of its experimental drug, VX-661. Last time the stock witnessed such as rapid growth was on November 3, 2000, when the prices reached $93.87 a share.

    It’s only Phase II

    The drug more »

  • Double-Digit Returns from the Biotechnology Strategy

    By Jeff Stouffer - May 7, 2013 | Tickers: NPSP, REGN, SNY, XBI, THRX, VRTX

    Investments in biotechnology by the average investor tend to deliver hit or miss returns over time. Since inception, the SPDR S&P Biotech ETF (NYSEMKT: XBI) has delivered double-digit returns. This ETF holds 53 stocks and is focused on this industry. Created on Jan. 31, 2006, the one-year return is 33.76%, the three-year return is 23.57%, and the five-year return is 13.27%. Only the one-month and three-month more »

  • Top Three Performing NASDAQ 100 Stocks for 2013

    By Naomi Warmate-Igwe - May 1, 2013 | Tickers: CELG, LIFE, VRTX

    It should come as no surprise that year to date, the top three performing NASDAQ 100 stocks come from companies in the health care sector. Through April 26th, those companies were Vertex Pharmaceuticals (NASDAQ: VRTX) Celgene Corporation (NASDAQ: CELG) and Life Technologies (NASDAQ: LIFE). As many analysts have predicted, the health care sector is performing exceptionally in 2013, asU.S. firms scramble for their piece of the pie in more »

  • 3 Healthcare Picks From Janus Fund

    By Reuben Brewer - April 30, 2013 | Tickers: ESRX, PRGO, VRTX

    Janus Fund (JANDX) bares the name of the fund family behind it. The flagship offering focuses on growth. Three healthcare stocks that underperformed for the fund in 2012 still appear to have growth potential.

    Growth

    Janus Fund focuses on growth. In its search for companies with “earnings growth potential that may not be recognized by the market at large,” management starts at the ground floor. Building its research and portfolio more »

  • This Biotech Just Popped, and Might Pop Further

    By Terry Chrisomalis - April 29, 2013 | Tickers: GILD, MRK, VRTX

    Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have appreciated significantly in 2013 so far, and it seems that the trend might continue for the rest of the year. Vertex is a biotech company focused on treating rare diseases with limited treatment options. Vertex has popped big recently on new promising data for patients diagnosed with Cystic fibrosis. 

    Cystic Fibrosis is a rare disease that causes thick mucus to build up in more »

  • Orphan Drug Biotechs Do It Best

    By Terry Chrisomalis - April 19, 2013 | Tickers: ALXN, BMRN, VRTX

    There are many biotech stocks to choose from that have long-lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drugs. You might ask why you should bother investing in this type of biotech stocks? Because these companies treat rare diseases with limited treatment options. 

    In my opinion, these biotech stocks perform better than their peers, and will more »

  • 2 Biotech Companies With Multi-Bagger Potential

    By Greg Williamson - April 18, 2013 | Tickers: CELG, EXEL, VRTX

    Some investors consider speculation to be a dirty word, but it can be an important component of a diversified portfolio. Although speculative stocks have an increased level of risk, they also have enormous reward potential. The following four keys will allow you to improve your chances of hitting a home run with speculative stocks, while ensuring that your portfolio is protected:

    1.) Limit your speculative holdings to between 10% to more »

  • Orphan Drug Biotechs Do It Best

    By Terry Chrisomalis - April 16, 2013 | Tickers: ALXN, BMRN, VRTX

    There are many biotech stocks to choose from that have long lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drug status. You might ask why invest in these types of biotech stocks? It is quite simple really, these types of companies treat rare diseases with limited treatment options. 

    In my opinion I feel these biotech stocks more »

  • Monday’s Market Moving Downgrades Worth Noting

    By Brian Nichols - April 10, 2013 | Tickers: CA, JNJ, VRTX

    Stocks can be pushed higher or lower as analysts provide their outlooks. These calls are not enough to make an investment, but should be considered as part of your research. Therefore, I am assessing a few of Monday’s top downgrades, and determining if each was a good call.

    Johnson & Johnson (NYSE: JNJ)

    Shares of Johnson & Johnson fell lower by 1.50% on Monday after JPMorgan downgraded the stock to more »

  • Monday’s Market Moving Downgrades Worth Noting

    By Brian Nichols - April 8, 2013 | Tickers: CA, JNJ, VRTX

    Stocks can be pushed higher or lower as analysts provide their outlooks. These calls are not enough to make an investment, but should be considered as part of your research. Therefore, I am assessing a few of Monday’s top downgrades, and determining if each was a good call.

    Johnson & Johnson (NYSE: JNJ)

    Shares of Johnson & Johnson fell lower by 1.50% on Monday after JPMorgan downgraded the stock to more »

  • Hepatitis C In Play for 2013?

    By Terry Chrisomalis - February 25, 2013 | Tickers: ACHN, BMY, IDIX, VRTX

    In the world of biotech stocks a lot of companies are starting to incorporate Hepatitis C treatments into their pipelines. Hepatitis C is starting to garner a lot of attention, and these biotech companies are not wrong to be chasing this target disease. Why, you ask? Because there are currently 170 million people worldwide infected with Hep C, and this could mean huge opportunity for biotech companies that are in more »

  • Disappointing Fourth Quarter - Reason to Sell?

    By Jordo Bivona - February 10, 2013 | Tickers: ACHN, GILD, PFE, VRTX

    Vertex Pharmaceuticals (NASDAQ: VRTX) saw sales of its hepatitis C drug, Incivek, drop sharply in the fourth quarter, year-on-year. This article will address the company's latest earnings release and its future prospects. The company attributes the decrease to patients with hepatitis C opting for alternative treatments through other available medicines. Incivek was approved by the FDA only in May 2011 and the decline emphasizes the cutthroat competitive business environment more »

  • Is Celgene's New Rally Sustainable?

    By Nicholas Kitonyi - January 15, 2013 | Tickers: CELG, JNJ, VRTX

    If you do not have it in your portfolio, then you probably want to take a look at this stock. With a 52 week low of $58.53, the company just recorded a new 52 week high last week. Specifically, during the early trading hours Tuesday 8, Celgene (NASDAQ: CELG) hit a high of $89 within a matter of minutes; and it just can’t stop rallying as it hit more »

  • The Most Important New Drug of 2012

    By Jordo Bivona - January 9, 2013 | Tickers: ACHN, GILD, IDIX, VRTX

    Forbes recently crowned Vertex Pharmaceuticals' (NASDAQ: VRTX) Kalydeco the most important new drug of 2012. Forbes said that Kalydeco, used to treat cystic fibrosis, is a triumph of genetics and drug development and the first treatment to directly address the genetic defect that causes the disease.

    Kalydeco will only help 4 percent of the 70,000 people who suffer from declining lung function, a damaged pancreas, and shortened lives due more »

  • Will Kalydeco Push Vertex Higher?

    By Jordo Bivona - December 13, 2012 | Tickers: ACHN, GILD, VRTX

    Vertex Pharmaceuticals (NASDAQ: VRTX) announced that Health Canada has approved Kalydeco (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Cystic fibrosis is a rare genetic disease for which there is no cure and is caused by a defective or missing more »

  • New Developments At Abbott Labs

    By Adam Levy - November 12, 2012 | Tickers: ABT, GILD, PFE, VRTX

    Abbott Labs (NYSE: ABT) has been in the news a lot lately. With an upcoming spinoff and new drug trial information coming out, the stock has analysts talking. Most recently, the company was featured on Thursday’s Mad Money, where Jim Cramer believed the company would create $10 per share in value to investors through the spinoff. As a result, the stock traded up over 2.5% on Friday before more »

  • Is Bain Capital Betting Against Mitt Romney?

    By Meena Krishnamsetty - October 10, 2012 | Tickers: AMRN, IDIX, MAPP, PFE, VRTX

    As debate season heats up, we had an interesting takeaway from the first 2012 Presidential debate. Obama failed to mention anything about Romney’s old firm, Bain Capital. That is not going to stop us from mentioning it—in the issues that Romney and Obama did discuss, Romney continued to take the hardline that he would repeal Obamacare if elected.

    As mentioned, the fact that Obama failed to discuss anything more »

  • Biotech Industry On The Upswing

    By Sharmistha Banerjee - October 3, 2012 | Tickers: REGN, SNY, VRTX

    There’s a huge surge at a record-setting pace in biotech employment at hundreds of companies, a recent survey shows. It’s estimated the industrial biotechnology sector will create 100,000 jobs in the United States during the next five years. The survey shows that hiring demand over the next 12 months among these companies is expected to be strongest for molecular/cell biologists, chemists, chemical engineers, fermentation specialists and more »

  • A Bunch of Hot Health Care Stocks

    By Lee Samaha - September 11, 2012 | Tickers: ACT, CVS, MYL, VRX, VRTX

    Sometimes successful investment themes seem to creep up unnoticed to most investors and only after the event do we realize that they were staring us in the face all along. One such idea is the specialty pharmaceutical sector. By this I mean generics, over the counter (OTC) manufacturers and generally those companies outside of the mainstream pharma and biotech sector. This sector has done very well this year and this more »

  • Three Missed ETFs that are Less Visible and Roar

    By Jeff Stouffer - September 4, 2012 | Tickers: ALXN, CZA, CCI, ETE, IWP, MDY, OKS, REGN, VRTX

    One of the most overlooked investment ideas is Mid-Cap stocks. Large-Cap stocks are clearly recognized by being components of the S&P 500 or the Dow Jones Industrial Average. Small-Cap stocks get notoriety from being part of either the Russell 200 or the S&P 600 SmallCap Index. Event thought there is the S&P MidCap 400 Index it seems to not get the same amount of attention, especially by more »

  • Page 1 of 2